About the Trial
Trial Name: A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
ClinicalTrials.gov ID: NCT05104866
Completion Date (Estimated): August 15, 2025
According to analysis results from the phase 3 clinical trial TROPION-Breast01 (NCT05104866), datopotamab deruxtecan (Dato-DXd; AstraZeneca, Daiichi Sankyo) did not achieve statistical significance in final overall survival (OS) results in patients with inoperable or metastatic hormone receptor-positive (HR+), HER2-low, or HER2-negative (HER2–; IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who were previously treated with endocrine-based therapy and at least 1 systemic therapy. Compared with investigator’s choice of chemotherapy, Dato-DXd had previously met the dual primary end point of progression-free survival (PFS).1
Dato-DXd is an investigational TROP2-directed antibody drug conjugate, and it is comprised of a humanized anti-TROP2 immunoglobulin G-1 monoclonal antibody. Currently, the agent is being investigated in multiple cancers, such as non-small cell lung cancer, triple-negative breast cancer, and HR+/HER2- breast cancer. Specifically, 7 phase 3 trials are being conducted in lung cancer and 5 phase 3 trials in breast cancer; these trials are evaluating Dato-DXd as a monotherapy and in combination with other anticancer treatments.1
For this global, randomized, multicenter, open-label, phase 3 clinical trial, investigators assessed the efficacy and safety of Dato-DXd compared with single-agent chemotherapy in adult patients who have unresectable or metastatic HR+, HER2-low, or HER2– (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer. The enrolled patients had all progressed on and are not considered suitable for further endocrine therapy—determined by an investigator assessment—and have received at least 1 additional systemic therapy for unresectable or metastatic disease.1,2
Patients were randomly assigned to receive either Dato-DXd (n=365) administered intravenously (IV), or investigator’s choice of chemotherapy (n=367) which consisted of either oral capecitabine (Xeloda; Genentech), IV gemcitabine (Gemzar; Eli Lilly & Co.), IV eribulin (Halaven; Eisai), or IV vinorelbine (Navelbine; Pierre Fabre Pharmaceuticals). Following disease progression or discontinuation of Dato-DXd or chemotherapy, patients were given the option to receive subsequent treatment if advised by their providers, but crossover between treatment groups was not permitted. The trial’s primary end points were PFS and OS, and secondary end points included objective response rate, duration of response, disease control rate, time to first subsequent and second subsequent therapy, among others.2,3